Abstract: The invention provides a method for suppressing tumor cell growth in a patient, comprising: administering to the patient an effective amount of an expression vector including a polynucleotide encoding a tumor suppressor protein having SEQ ID NO: 1 under conditions wherein the expression vector incorporates itself into the tumor cell genome and inhibits cell proliferation or induces cell death. The invention further provides a method for a method for inhibiting tumor cell proliferation in a tumor cell population comprising: administering to the tumor cell population an amount of a composition comprising a tumor suppressor protein having SEQ ID NO: 1 effective to inhibit tumor cell proliferation therein.
Abstract: CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions.
Type:
Grant
Filed:
December 13, 2005
Date of Patent:
September 28, 2010
Assignee:
GlaxoSmithKline Biologicals S.A.
Inventors:
Teresa Elisa Virginia Cabezon-Silva, Jean-Pol Cassart, Thierry Coche, Swann Romain Jean-Thomas Gaulis, Carlota Vinals Y De Bassols
Abstract: A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.
Type:
Grant
Filed:
May 21, 2007
Date of Patent:
September 14, 2010
Assignee:
Agensys, Inc.
Inventors:
Aya Jakobovits, Arthur B. Raitano, Daniel E. H. Afar, Douglas Saffran, Rene S. Hubert, Mary Faris, Pia M. Challita-Eid
Abstract: The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.
Type:
Grant
Filed:
February 8, 2007
Date of Patent:
September 7, 2010
Assignee:
Sanofi Pasteur Limited
Inventors:
Neil Berinstein, Devender Singh-Sandhu, Corey Lovitt, Artur Pedyczak, Laszlo Radvanyi
Abstract: The invention provides the identification and characterization of disease and cancer-associated epitope, KID3. The invention also provides a family of monoclonal antibodies that bind to KID3, methods of diagnosing and treating various human cancers and diseases that express KID3.
Type:
Grant
Filed:
September 17, 2004
Date of Patent:
September 7, 2010
Assignee:
MacroGenics, Inc.
Inventors:
Tony W. Liang, Deryk T. Loo, Xiaolin Xu
Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.
Type:
Grant
Filed:
May 11, 2005
Date of Patent:
August 31, 2010
Assignee:
Ganymed Pharmaceuticals, AG
Inventors:
Özlem Türeci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schlüter, Dirk Usener, Philippe Thiel, Michael Koslowski
Abstract: This invention relates to isolated peptides derived from MAGE-C2, nucleic acid molecules that encode MAGE-C2 and the isolated peptides derived from MAGE-C2, expression vectors comprising the nucleic acid molecules, host cells transformed or transfected with the nucleic acid molecules or the expression vectors, and to tetramers comprising the peptides, HLA molecules, ?2 microglobulin and a first and second binding partner. This invention also relates to methods for using the peptides, nucleic acid molecules, expression vectors, tetramers and complexes of this invention as well as to cytolytic T cells which recognize the peptides in complex with an HLA molecule.
Type:
Grant
Filed:
January 29, 2008
Date of Patent:
August 31, 2010
Assignee:
Ludwig Institute for Cancer Research
Inventors:
Aline Van Pel, Daniele Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon-Falleur
Abstract: The present invention relates to a novel protein designated 20P2H8 which shares homology with several heterogeneous nuclear ribonucleoproteins (hnRNPs). A full length approximately 3600 bp 20P2H8 cDNA (SEQ ID NO: 1, encoding a 517 amino acid open reading frame (SEQ ID NO: 2), is provided herein.
Type:
Grant
Filed:
July 9, 2008
Date of Patent:
August 10, 2010
Assignee:
Agensys, Inc.
Inventors:
Daniel E. H. Afar, Arthur B. Raitano, Rene S. Hubert, Steve Chappell Mitchell, Aya Jakobovits
Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
Type:
Grant
Filed:
September 29, 2004
Date of Patent:
August 3, 2010
Assignee:
Genentech, Inc.
Inventors:
Gretchen Frantz, Paul Polakis, Susan D. Spencer, Thomas D. Wu, Zemin Zhang
Abstract: The present invention describes a method for diagnosing tumours of the reproductive organs which is characterised by determination of the afamin content in a sample of a body fluid or in a tissue sample, wherein a tumour is diagnosed if the afamin content in the sample is decreased compared to the afamin content in a sample from a person without a tumour of the reproductive organs.
Abstract: The invention provides the mutants and coding genes of trichosanthin (TCS). The mutants thereof are the TCS mutants with the single or double alternation of tyrosine-55 and aspartate-78 (counted from N-terminus), wherein the tyrosine-55 is mutated to an aliphatic amino acid and aspartate-78 is mutated to an amino acid with low hydrophilicity. This invention also relates to the application of TCS mutants and their coding genes in the drug development to treat carcinoma, AIDS and other diseases.
Type:
Grant
Filed:
August 4, 2005
Date of Patent:
July 27, 2010
Inventors:
Chengcai An, Shuangli Mi, Ye Wang, Yin Gao
Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.
Type:
Grant
Filed:
October 30, 2007
Date of Patent:
July 6, 2010
Assignee:
Corixa Corporation
Inventors:
Tongtong Wang, Robert A. Henderson, Teresa M. Foy
Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
Type:
Grant
Filed:
April 10, 2002
Date of Patent:
June 15, 2010
Assignee:
Agensys, Inc.
Inventors:
Aya Jakobovits, Pia M. Challita-Eid, Mary Faris, Wangmao Ge, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Arthur B. Raitano, Daniel E. H. Afar
Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha emitting constructs have high specific activity.
Type:
Grant
Filed:
November 24, 2000
Date of Patent:
June 15, 2010
Assignee:
Sloan-Kettering Institute for Cancer Research
Inventors:
David Scheinberg, Dangshe Ma, Michael R. McDevitt, George Sgouros
Abstract: The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCR $g(a) chain, except the transmembrane domain thereof, and (ii) all or part of a TCR $g(b) chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and at least a part of the constant domain of the TCR chain, and are linked by a disulphide bond between constant domain residues which is not present in native TCR, characterized in that the sTCR recognizes a CD1-antigen complex, a bacterial superantigen or a peptide-MHC/superantigen complex.
Abstract: Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer.
Type:
Grant
Filed:
February 23, 2001
Date of Patent:
February 9, 2010
Assignee:
Hybritech Incorporated
Inventors:
Stephen D. Mikolajczyk, Harry G. Rittenhouse, Tang Jang Wang, Robert L. Wolfert
Abstract: This invention relates to a gene encoding RTVP that has been shown to be up-regulated by p53 using differential display-PCR and subsequently by co-transfection studies. RTVP-1 mRNA is abundant in normal mouse and human prostatic epithelial cells and primary tumors, but is significantly down regulated in metastatic mouse and human prostate cancer. In prostate cancer cells overexpression of the mouse RTVP-1 gene (mRTVP-1) induced apoptosis that was accompanied by increased caspase 8, 9 and 3 activities. mRTVP-1-stimulated apoptosis was also associated with increased levels of bax, bad and activated BID; reduced levels of bcl-2 and bcl-XL; and cytosolic cytochrome c accumulation. Adenoviral-vector-mediated mRTVP-1 expression lead to potent growth suppression and antimetastatic activities in an orthotopic mouse model of prostate cancer in vivo. These therapeutic activities were associated with anti-angiogenic effects and importantly a local and systemic immune response.
Abstract: We describe a polypeptide which binds and modulates the activity of a tumour suppressor polypeptide, for example p53; a nucleic acid molecule encoding said protein and screening methods which modulate the binding activity of said polypeptide for its target polypeptide(s).